Knights of Columbus Asset Advisors LLC Invests $1.46 Million in ShockWave Medical, Inc. (NASDAQ:SWAV)

Knights of Columbus Asset Advisors LLC purchased a new position in shares of ShockWave Medical, Inc. (NASDAQ:SWAV) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 7,086 shares of the company’s stock, valued at approximately $1,459,000.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of ShockWave Medical by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 2,975,782 shares of the company’s stock worth $564,594,000 after acquiring an additional 86,004 shares during the period. BlackRock Inc. lifted its holdings in ShockWave Medical by 1.3% during the 3rd quarter. BlackRock Inc. now owns 2,574,165 shares of the company’s stock worth $529,970,000 after purchasing an additional 32,988 shares in the last quarter. Lord Abbett & CO. LLC lifted its holdings in ShockWave Medical by 12.2% during the 2nd quarter. Lord Abbett & CO. LLC now owns 911,475 shares of the company’s stock worth $172,934,000 after purchasing an additional 99,246 shares in the last quarter. State Street Corp lifted its holdings in ShockWave Medical by 10.8% during the 2nd quarter. State Street Corp now owns 684,923 shares of the company’s stock worth $129,950,000 after purchasing an additional 66,813 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in ShockWave Medical by 2,438.5% during the 2nd quarter. Invesco Ltd. now owns 606,503 shares of the company’s stock worth $115,071,000 after purchasing an additional 582,611 shares in the last quarter. Institutional investors own 90.93% of the company’s stock.

NASDAQ:SWAV opened at $166.98 on Friday. The business’s 50-day moving average price is $187.08 and its two-hundred day moving average price is $195.63. ShockWave Medical, Inc. has a twelve month low of $91.46 and a twelve month high of $249.73. The company has a quick ratio of 5.40, a current ratio of 6.36 and a debt-to-equity ratio of 0.06.

ShockWave Medical (NASDAQ:SWAV) last announced its quarterly earnings data on Monday, November 8th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.12. The firm had revenue of $65.16 million for the quarter, compared to analyst estimates of $61.21 million. ShockWave Medical had a negative return on equity of 17.68% and a negative net margin of 21.60%. The company’s revenue was up 232.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.38) EPS. On average, analysts expect that ShockWave Medical, Inc. will post -0.54 EPS for the current year.

In other news, Director Frank T. Watkins sold 2,000 shares of the stock in a transaction dated Tuesday, October 19th. The stock was sold at an average price of $201.37, for a total transaction of $402,740.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Douglas Evan Godshall sold 45,000 shares of the stock in a transaction dated Thursday, November 18th. The shares were sold at an average price of $207.28, for a total value of $9,327,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 78,200 shares of company stock worth $15,367,951 over the last quarter. Corporate insiders own 15.30% of the company’s stock.

A number of analysts recently issued reports on SWAV shares. SVB Leerink increased their price objective on ShockWave Medical from $250.00 to $265.00 and gave the stock an “outperform” rating in a report on Tuesday, November 9th. Zacks Investment Research raised ShockWave Medical from a “hold” rating to a “strong-buy” rating and set a $203.00 price objective on the stock in a report on Wednesday. Piper Sandler increased their price objective on ShockWave Medical from $225.00 to $272.00 and gave the stock an “overweight” rating in a report on Tuesday, November 9th. raised their price target on ShockWave Medical from $219.00 to $258.00 and gave the company a “buy” rating in a report on Tuesday, November 9th. Finally, Wells Fargo & Company raised ShockWave Medical from an “equal weight” rating to an “overweight” rating and set a $235.00 price target on the stock in a report on Monday, December 6th. Three analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $234.71.

About ShockWave Medical

Shockwave Medical, Inc operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Read More: Percentage Gainers

Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ShockWave Medical, Inc. (NASDAQ:SWAV).

Institutional Ownership by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.